LFn p24 B C

Drug Profile

LFn p24 B C

Alternative Names: HIV vaccine - Haikou VTI; LFn-p24-B-C; LFnp24B.C

Latest Information Update: 02 May 2016

Price : $50

At a glance

  • Originator Harvard University
  • Developer Haikou VTI Biological Institute; Harvard University
  • Class AIDS vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Human immunodeficiency virus gag gene product inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV-1 infections

Most Recent Events

  • 10 Apr 2016 Haikou VTI completes a phase I trial in HIV-1 infections (Adjunctive treatment) in China (IM) (ChiCTR-TRC-14004485)
  • 11 Mar 2016 This programme is still active
  • 02 May 2014 Clinical trials in HIV-1 infections (adjunctive treatment) in Uganda prior to May 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top